Diamyd Medical AB (publ) (FRA:DMN)

Market Cap	125.76M
Revenue (ttm)	11.73K
Net Income (ttm)	-15.32M
Shares Out	n/a
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	21.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	23
Open	0.9050
Previous Close	0.8900
Day's Range	0.9050 - 0.9420
52-Week Range	0.6490 - 1.6240
Beta	n/a
RSI	61.23
Earnings Date	Jan 28, 2026

About Diamyd Medical AB

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to devel...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 39
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DMN

Financial Performance

In 2025, Diamyd Medical AB's revenue was 130,000, a change of 0.00% compared to the previous year's 130,000. Losses were -169.78 million, 11.8% more than in 2024.

Financial numbers in SEK